Effects of hydrochlorothiazide on kidney stone therapy with extracorporeal shock wave lithotripsy - Abstract

OBJECTIVE: The aim of this investigation was to assess the efficacy of hydrochlorothiazide as a hypocalciuric diuretic on stone-free rate of renal pelvic calculi after extracorporeal shock wave lithotripsy (ESWL).

MATERIALS AND METHODS: A double-blind, placebo-controlled randomized clinical trial was conducted and 52 patients with renal pelvic calculi (diameter ≤ 2 cm) were enrolled from February 2010 to September 2010. ESWL protocol was performed by 2,500 shocks per session. The patients were randomized into two groups: (1) 26 patients who were given 25 mg hydrochlorothiazide twice daily; and (2) 26 patients who received placebo. The stone-free rate was defined as residual calculus size ≤ 4 mm in controlled ultrasound on 2nd week, 1 month and 3 months after ESWL.

RESULTS: 19 (78%) of the first group and 9 (42.9%) of the second group were stone-free after one session of ESWL (P = 0.02). 88% of the group 1 and 47.8% of the group 2 were stone-free on 1 month after ESWL (P = 0.003); however, this effect of hydrochlorothiazide was not related to the patients' body mass index, age and gender. The accessory treatment procedures were applied in 24% of the group 1 compared with 19% of the group 2 during 3 months (P = 0.68). All patients in both groups were stone-free on 3 months following lithotripsy.

CONCLUSIONS: Hydrochlorothiazide did not impact on the stone-free rate and using accessory procedure within 3 months; however, it decreased duration of stone-free status and number of ESWL sessions.

Written by:
Tehranchi A, Rezaei Y, Mohammadi-Fallah M, Mokhtari M, Alizadeh M, Abedi F, Khalilzadeh M, Tehranchi P.   Are you the author?
Department of Urology, Urmia Urology and Nephrology Research Center, Urmia University of Medical Sciences, Urmia, Iran.

Reference: Urol Ann. 2014 Jul;6(3):208-11.
doi: 10.4103/0974-7796.134261


PubMed Abstract
PMID: 25125892

UroToday.com Stone Disease Section